Supplementary Figure 8: Pharmacokinetics and safety profile of AmpB in mice, and CD133 and nestin-positive cells in the tumor core of mice implanted with mouse GL261 BTICs.

Serum (a) and brain (b) level of AmpB in mice, measured using HPLC, following 30 days of AmpB treatment (n=5 for all groups). (c) Differential counts of blood cells, showing elevated level of monocytes, in mice injected with daily AmpB for 30 days; mice were not neutropenic with AmpB treatment, n=5 for all groups, with unpaired t-test. (d,e) In another group of tumor bearing mice injected with daily AmpB for 50 days, normal renal and liver function tests (using Multistix10SG, Bayer Health Care, Elkhart, IN) in urine were demonstrated; these mice had elevation of monocytes in blood consistent with AmpB being a stimulator of monocytoid cells, but normal neutrophil counts. Mean ± s.d. n of 4, with unpaired t-test. (f) Representative images from the brains of C57BL/6 mice that died from the GL261 BTIC implantation of Figure 7. CD133 (red) and nuclear yellow (blue) stain in a region of no tumor (NT) or within the tumor core (TC). Nuclear yellow (blue) stain depicting the tumor mass in the top right hand corner whereby when stained for nestin (green), this stem-like marker was found only in the tumor core (TC). Comparable images were seen in vehicle- or AmpB-treated mice when these were moribund from the tumor and sacrificed.